GRCE Grace Therapeutics Inc.

Price (delayed)

$2.4

Market cap

$37.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.31

Enterprise value

$18.47M

?
Relative Growth: Rel. Growth: 18
Relative Strength: Rel. Strength: 13
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 15
Highlights
Grace Therapeutics's quick ratio has surged by 153% YoY and by 7% QoQ
The EPS has surged by 73% year-on-year and by 42% since the previous quarter

Key stats

What are the main financial stats of GRCE

GRCE stock price

How has the Grace Therapeutics stock price performed over time
Intraday
-2.04%
1 week
-1.23%
1 month
1.69%
1 year
-16.67%
YTD
-30.64%
QTD
-48.16%

Financial performance

How have Grace Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$11.52M
Net income
-$5.98M
Gross margin
N/A
Net margin
N/A
Grace Therapeutics's net income has soared by 55% YoY and by 24% from the previous quarter
GRCE's operating income is up by 24% year-on-year and by 10% since the previous quarter

Price vs fundamentals

How does GRCE's price correlate with its fundamentals

Growth

What is Grace Therapeutics's growth rate over time

Valuation

What is Grace Therapeutics stock price valuation
P/E
N/A
P/B
0.52
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 73% year-on-year and by 42% since the previous quarter
The company's equity rose by 24% YoY and by 3.3% QoQ
The stock's P/B is 12% below its 5-year quarterly average of 0.6 and 12% below its last 4 quarters average of 0.6

Efficiency

How efficient is Grace Therapeutics business performance
The ROE has soared by 60% YoY and by 27% from the previous quarter
The ROA has soared by 57% YoY and by 26% from the previous quarter

Dividends

What is GRCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GRCE.

Financial health

How did Grace Therapeutics financials performed over time
Grace Therapeutics's quick ratio has surged by 153% YoY and by 7% QoQ
The company's current ratio has surged by 147% YoY and by 8% QoQ
The debt is 100% lower than the equity
The company's equity rose by 24% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.